ExoBDNF Probiotic Supplementation Enhances Cognition in Subjective Cognitive Decline

TL;DR

A new probiotic called ExoBDNF improved memory, sleep, and mood in people with early signs of cognitive decline.

Contribution

This study introduces ExoBDNF as a novel probiotic that enhances cognition and emotional well-being through the gut-brain axis.

Findings

ExoBDNF improved subjective cognition, sleep quality, and emotional distress in participants with SCD.

Cognitive performance improved, particularly in executive function and MoCA scores.

Higher baseline SCD scores predicted greater emotional improvement after ExoBDNF supplementation.

Abstract

Background and Objectives: Interventions targeting the gut–brain axis offer potential for mitigating Subjective Cognitive Decline (SCD), a critical window for Alzheimer’s prevention. This study evaluated the effects of a novel probiotic supplement, ExoBDNF, on cognitive function, sleep, and emotional distress in adults with SCD. Materials and Methods: In this 9-week open-label study, participants received ExoBDNF supplementation. Efficacy was assessed using the SCD-Questionnaire (SCD-Q), DASS-21, PSQI, MoCA, and a computerized cognitive battery measuring inhibition (Go/No-Go), flexibility (Task Switching), and working memory. Results: Post-intervention analyses revealed significant improvements in subjective cognition (SCD-Q, p < 0.001), sleep quality (PSQI, p < 0.001), and emotional distress (DASS-21, p < 0.001). Objective cognitive performance also improved, with significant gains in MoCA scores (p = 0.047) and executive function metrics. Spearman correlation analysis indicated a significant link between cognitive and emotional changes: longitudinal reductions in SCD scores correlated with concurrent reductions in emotional distress (rho = 0.471, p = 0.009). Furthermore, higher baseline SCD scores predicted greater improvement in emotional outcomes (rho = −0.540, p = 0.002). Conclusions: ExoBDNF supplementation significantly enhanced cognitive performance, sleep quality, and emotional well-being. The findings demonstrate that improvements in subjective cognition are closely tied to alleviated emotional distress, supporting the gut–brain axis as a viable therapeutic target for early-stage cognitive decline.

Figures